A fight even after the backlash. At the 5th Next Generation Gene Therapy Immunogenicity Summit, it was announced that data showing tolerability of the immune response and sustainable therapeutic effects of MDL-101 (epigenome editing technology using CRISPR) is scheduled to be presented. It is data that strongly shows the safety of systemic administration of vectors expressing foreign proteins, and at the same time that MDL-101 may be an innovative treatment for LAMA2-CMD, it strongly suggests that CRISPR-GNDM can be applied as a revolutionary basic technology for systemic genetic diseases.
モダリス---反発後もみ合い、「MDL-101」の前臨床データなどを発表予定
Modaris - Expected to announce preclinical data for 'MDL-101' despite a tug-of-war after the rebound.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.